Perforation of the right ventricular free wall by an ICD lead in a patient with isolated noncompaction of the ventricular myocardium.

Yoshitaka Sakai,Yuichi Sato,S. Matsuo,S. Imai,T. Kunimasa,N. Matsumoto,S. Saito

DOI: https://doi.org/10.1016/J.IJCARD.2006.11.223

IF: 4.039

2007-05-02

International Journal of Cardiology

Abstract:

What problem does this paper attempt to address?

Effect of Sildenafil in Neonates with Persistent Pulmonary Hypertension: An Interventional Study

Jigar Jain,Jolly Vaishnav,Arif Vohra,Mansi Shah,Anika Goyal

DOI: https://doi.org/10.7860/ijnmr/2024/67870.2415

2024-01-01

Indian Journal of Neonatal Medicine and Research

Abstract:Introduction: Persistent Pulmonary Hypertension of the Newborn (PPHN) reflects a disruption of the normal perinatal circulatory transition and is characterised by high pulmonary artery pressure. Inhaled Nitric Oxide (iNO) is considered the mainstay of treatment for PPHN. However, many developing and resource limited countries do not have access to such expensive therapy. Therefore, sildenafil, due to its easy availability and low cost, becomes the most commonly used drug in the management of PPHN in such settings. Aim: To study the treatment response and outcomes of neonates who received sildenafil for the management of PPHN. Materials and Methods: The present hospital-based prospective interventional study was conducted in the Neonatal Intensive Care Unit (NICU), BJ Medical College, Civil Hospital, Ahmedabad, Gujarat, between May 1, 2020, and April 30, 2021. Study was conducted on neonates with meconium aspiration syndrome and/or severe birth asphyxia admitted to the NICU. A total of 48 neonates with Two Dimensional (2D) echocardiography-proven PPHN were enrolled. Baseline clinical parameters including heart rate, respiratory rate, preductal and postductal Saturation of Peripheral Oxygen (SpO2), Oxygenation Index (OI), Saturation Oxygen Distending Pressure Index (SOPI), and Non Invasive Blood Pressure (NIBP) were monitored every six hours. Neonates who were on invasive/ non invasive ventilation had their Fraction of Inspired Oxygen (FiO2), Positive End Expiratory Pressure (PEEP), Peak Inspiratory Pressure (PIP), respiratory rate and flow rate monitored every six hours. Data were statistically analysed using Analysis of Variance (ANOVA) test. Results: During the study period, a total of 1080 neonates were admitted with meconium aspiration syndrome and/or severe birth asphyxia, out of which 48 neonates showed findings suggestive of PPHN on 2D echocardiography. A statistically significant improvement in oxygenation after sildenafil treatment was indicated by a significant reduction in OI from 35.3±8.6 to 13.2±2.1 (p-value<0.001), a reduction in SOPI from 3.6±0.3 to 1.5±0.2 (p-value<0.001), a reduction in FiO2 (%) from 94.6±8.19 to 24.2±4.5 (p-value<0.001), an increase in Partial pressure of oxygen (PaO2) (mmHg) from 52±5.6 to 72±3.4 (p-value<0.001), and an increase in SpO2 (%) from 83.5±8.6 to 93.5±5.1 (p-value<0.001). Conclusion: The findings of the present study suggest that oral sildenafil can be successfully used to improve oxygenation in patients with PPHN, especially in a resource limited setting where facilities like Extracorporeal Membrane Oxygenation (ECMO) and iNO are not available, as demonstrated in the present study.
Efficacy of sildenafil in persistent pulmonary hypertension of the newborn.

Muhammad Naveed,Fazal ur Rehman,Khurram Shahnawaz,Farhan Zahoor,Bushra Madni,Muhammad Imran

DOI: https://doi.org/10.29309/tpmj/2022.29.04.6617

2022-03-31

The Professional Medical Journal

Abstract:Objective: To find out efficacy of sildenafil for the treatment of persistent pulmonary hypertension of the newborn (PPHN). Study Design: Observational study. Setting: Department of Neonatology, Sughra Shafi Medical Complex, Sahara Medical College, Narowal. Period: May 2020 to April 2021. Material & Methods: A total of 22 neonates of both genders with diagnosis of PPHN were enrolled during the study period. Demographic characteristic along with information about perinatal and postnatal characteristics were recorded among all neonates at the time of admission. X-ray chest were asked. Oral sildenafil was administered as 2mg/kg per dose thrice a day to all study cases and continued till extubation. Outcome was recorded on the basis of difference in FiO2 need after initiating sildenafil, time required to get ventilator off or mortality. Results: Out of a total of 22 neonates, 13 (59.1%) were male. Majority of the neonates, 15 (68.2%) were term newborns. Mode of delivery was lower segment cesarean section in 17 (77.3%) cases. APGAR score at 5 minutes was between 7 to 10 in 13 (59.1%) newborns. There were 13 (59.1%) newborns who required immediate resuscitation following birth. Meconium aspiration syndrome was the commonest associated condition found among 8 (36.4%) neonates. As per echocardiographic findings, 13 (59.1%) neonates had severe PPHN, 5 (22.7%) moderate and 4 (18.2%) mild. Mean oxygenation index at the time of admission was noted to be 46+14. Inotropic support was administered to 19 (86.4%) cases. Mean length of neonatal intensive care unit was 15+5 days. Mortality was reported among 10 (45.4%) neonates. Conclusion: Oral sildenafil was found to be a promising option for the treatment of neonates having PPHN. Oral sildenafil was found to successfully improve oxygenation among neonates having PPHN.
Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital

Amber Kamran,Nida Rafiq,Adeel Khalid,Fatima Amin,Veena Kumari,Abdul Sattar Shaikh,Sameer Saleem Tebha,Najma Patel

DOI: https://doi.org/10.1080/14767058.2021.1923003

2021-05-12

Abstract:The prevalence of persistent pulmonary hypertension of newborn (PPHN) has been estimated 1.9/1000 live births. Although the efficacy of inhaled nitric oxide and extracorporeal membrane oxygenation in PPHN is well established but it is difficult to administer and monitor in resource limited countries. Owing to this, other treatment options need to be evaluated.This is a prospective observational study conducted in the Pediatric Cardiology Department, NICVD, Karachi, from February 2020 to October 2020 after the approval from the Institutional Ethical Review Committee. All the neonates referred to our Unit were screened by echocardiography (echo) and those who fulfilled the inclusion criteria were included. Echo were done before starting sildenafil and after 72 h to assess the pressure gradient across tricuspid valve and right to left or bidirectional shunt across patent ductus arteriosus , patent foramen ovale , or both. Sildenafil was started with a dose of 1 mg/kg/dose thrice a day and increased to 2 mg/kg/dose after 48 h if partial pressure of oxygen (PO<a href="#">1</a> Thérèse P. Persistent pulmonary hypertension of the newborn. Paediatr Respir Rev. 2006;7:175–176.<a href="/servlet/linkout?suffix=CIT0001&dbid=16&doi=10.1080%2F14767058.2021.1923003&key=10.1016%2Fj.prrv.2006.04.211">[Crossref]</a>, <a href="/servlet/linkout?suffix=CIT0001&dbid=8&doi=10.1080%2F14767058.2021.1923003&key=16938639">[PubMed]</a> , <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=175-176&author=P.+Th%C3%A9r%C3%A8se&title=Persistent+pulmonary+hypertension+of+the+newborn">[Google Scholar]</a>] did not increase. In neonates who did not respond to increased dose of Sildenafil were added on oral Bosentan 1 mg/kg/dose twice a day.Total 82 newborns were enrolled. Fifty-two patients improved after 48 h so were continued on same treatment. Sildenafil dose was increased in 30 (37.9%) patients whose PO2 did not increase to at least 10% from baseline after 48 h of starting treatment. Three patients expired within 48–72 h. Out of 27 remaining patients, only four responded whereas 23 patients did not show any improvement. In these patients, Bosentan was supplemented along with sildenafil.The results of our study show effectiveness of oral Sildenafil in treating PPHN. The overall improvement observed in the patients was overwhelming. Combination of Sildenafil with Bosentan is beneficial in patients who did not respond on Sildenafil alone.
Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study

Hernando Baquero,Amed Soliz,Freddy Neira,Maria E. Venegas,Augusto Sola

DOI: https://doi.org/10.1542/peds.2005-0523

2006-04-01

PEDIATRICS

Abstract:BACKGROUND. Persistent pulmonary hypertension (PPHN) occurs in as many as 6.8 of 1000 live births. Mortality is ∼10% to 20% with high-frequency ventilation, surfactant, inhaled nitric oxide, and extracorporeal membrane oxygenation but is much higher when these therapies are not available. Sildenafil is a phosphodiesterase inhibitor type 5 that selectively reduces pulmonary vascular resistance. OBJECTIVE. Our goal was to evaluate the feasibility of using oral sildenafil and its effect on oxygenation in PPHN. DESIGN. This study was a proof-of-concept, randomized, masked study in infants >35.5 weeks' gestation and <3 days old with severe PPHN and oxygenation index (OI) >25 admitted to the NICU (Hospital Niño Jesús, Barranquilla, Colombia). The sildenafil solution was prepared from a 50-mg tablet. The first dose (1 mg/kg) or placebo was given by orogastric tube <30 minutes after randomization and every 6 hours. Preductal saturation and blood pressure were monitored continuously. OI was calculated every 6 hours. The main outcome variable was the effect of oral sildenafil on oxygenation. Sildenafil or placebo was discontinued when OI was <20 or if there was no significant change in OI after 36 hours. RESULTS. Six infants with an OI of >25 received placebo, and 7 received oral sildenafil at a median age of 25 hours. All infants were severely ill, on fraction of inspired oxygen 1.0, and with similar ventilatory parameters. Intragastric sildenafil and placebo were well tolerated. In the treatment group, OI improved in all infants within 6 to 30 hours, all showed a steady improvement in pulse oxygen saturation over time, and none had noticeable effect on blood pressure; 6 of 7 survived. In the placebo group, 1 of 6 infants survived. CONCLUSIONS. Oral sildenafil was administered easily and tolerated as well as placebo and improved OI in infants with severe PPHN, which suggests that oral sildenafil may be effective in the treatment of PPHN and underscores the need for a large, controlled trial.

pediatrics
The outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn with respiratory distress

Esaad M. Monazea,Sahar S. Khattab,Asmaa A.W. Ebrahim,Layla A. Mohamed,Howayda A.A.R. Ahmed

DOI: https://doi.org/10.4103/sjamf.sjamf_72_20

2020-01-01

The Scientific Journal of Al-Azhar Medical Faculty, Girls

Abstract:Background Persistent pulmonary hypertension (PPHN) is defined as failure of normal pulmonary vascular adaptation at or soon after birth, resulting in a persistent high pulmonary vascular resistance, which leads to diminished pulmonary blood flow and shunting of unoxygenated blood into systemic circulation through an opened foramen ovale and/or the ductus arteriosus. The prevalence of this syndrome is about 1.9/1000 in the population of neonates born at term. Objective The aim was to evaluate the efficacy and safety of oral sildenafil in the treatment of PPHN. Patients and methods This prospective interventional study was conducted on 50 neonates who were of more than or equal to 37 weeks gestational age and less than 3 days old and were diagnosed as PPHN by echocardiogram and had an oxygenation index (OI) more than or equal to 20. All included cases were given oral sildenafil as per the study protocol with a starting dose of 0.5–2 mg/kg/dose. OI, oxygen saturation, alveolar arterial oxygen gradient, and mean airway pressure were monitored serially. Results This study showed a significant decrease in OI after 30 min of starting treatment and after 24 h of treatment in the studied cases 16.1±1.7 ( P =0.010); also, there was a significant decrease in ESPAP ? after treatment estimated by ECHO from mean 49.4±5,9 to 42.5±5.7 ( P <0.001). Furthermore, this study showed a significant decrease in brain-type natriuretic peptide in studied cases after treatment with sildenafil. Conclusion Oral sildenafil may be of benefit in improving oxygenation in infants with PPHN as it can effectively improve OI and reduce right ventricular systolic pressure.
The use of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Review of the Literature

Nicoletta Iacovidou,Aggeliki Syggelou,Vassilios Fanos,Theodoros Xanthos

DOI: https://doi.org/10.2174/1381612811209023034

IF: 3.31

2012-05-01

Current Pharmaceutical Design

Abstract:Persistent pulmonary hypertension of the newborn (PPHN) is a serious and potentially fatal condition, characterized by hypoxemia due to increased pulmonary vascular resistance (PVR) with resultant shunting of pulmonary blood to the systemic circulation. Inhaled nitric oxide (iNO) has been considered a revolutionary treatment of PPHN. Data show that the use of iNO has reduced the need of ECMO in neonates with severe PPHN, while in moderate PPHN, iNO administration has been associated with a significant decrease in ventilatory support and prevented progression to severe PPHN. Not all neonates respond to iNO therapy though, and phosphodiesterase (PDE) inhibitors with their potent vasodilator properties have evolved as an alternative therapy or as an adjunct to the treatment of PPHN with iNO. There are ten families of PDE isoenzymes. PDE 5 is particularly prevalent in vascular smooth muscle (VSM) and PDE 5 inhibitors, such as sildenafil, have been used in clinical practice. This review provides a comprehensive account of existing data in the literature, from animal and clinical studies, on the use of sildenafil for the treatment of PPHN. Sildenafil may also have a role as a single mode of therapy, since in resource-limited settings the cost of iNO is a serious concern.

pharmacology & pharmacy
Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial

Christine M Pierce,Min H Zhang,Baldvin Jonsson,Dinu Iorga,Narayan Cheruvu,Cecile C Balagtas,Robin H Steinhorn

DOI: https://doi.org/10.1016/j.jpeds.2021.05.051

Abstract:Objective: To investigate the efficacy and safety of sildenafil added to inhaled nitric oxide (iNO) for newborn infants with persistent pulmonary hypertension of newborn (PPHN) or hypoxic respiratory failure (HRF) at risk of PPHN. Study design: Part A of a multinational, randomized, double-blind, placebo-controlled trial. Infants ≤96 hours' old, >34 weeks of gestation, receiving iNO (10-20 ppm on ≥50% FiO2) for PPHN or HRF at risk of PPHN, and oxygen index >15 to <60, were randomized (1:1) to intravenous (IV) sildenafil (loading: 0.1 mg/kg, over 30 minutes; maintenance: 0.03 mg/kg/h) or placebo, for up to 14 days. Coprimary end points were treatment failure rate (day 14/discharge) and time on iNO without treatment failure. Secondary end points included time on ventilation and oxygenation measures. Results: Of 87 infants screened, 29 were randomized to IV sildenafil and 30 to placebo; 13 discontinued treatment (sildenafil, n = 6; placebo: n = 7), including 3 deaths (sildenafil: n = 2; placebo: n = 1). Treatment failure rates did not differ with sildenafil (27.6%) vs placebo (20.0%; P = .4935). Mean time on iNO was not different with sildenafil (4.1 days) vs placebo (4.1 days; P = .9850). No differences were noted in secondary end points. Most common adverse events (AEs) with sildenafil (≥10% infants) were hypotension (n = 8/29), hypokalemia (n = 7/29), anemia, drug withdrawal syndrome (n = 4/29, each), and bradycardia (n = 3/29). One serious AE (hypotension) was considered treatment-related. Conclusions: IV sildenafil added to iNO was not superior to placebo in infants with PPHN or HRF at risk of PPHN. A review of AEs did not identify any pattern of events indicative of a safety concern with IV sildenafil. Infants will have developmental follow-up (Part B). TRIAL REGISTRATION CLINICALTRIALS.GOV: NCT01720524.
Effect of Sildenafil on Mortality in Term Neonates with Hypoxemic Respiratory Failure due to Persistent Pulmonary Hypertension (SIPHON) - A Randomised Control Trial

Deepti Thandaveshwara,Sushma Krishnegowda,Divya Hosur,Srinivasa Murthy Doreswamy

DOI: https://doi.org/10.3126/jnps.v41i2.32403

2021-11-03

Journal of Nepal Paediatric Society

Abstract:Introduction: Persistent Pulmonary Hypertension (PPHN) complicates the transition from intrauterine to extrauterine life in some neonates. Sildenafil is known to reduce pulmonary pressures. However, its effect on reducing mortality is unclear. This study is conducted to determine the effect of Sildenafil in reducing all-cause mortality rate in term newborns with hypoxemic respiratory failure due to pulmonary hypertension. Methods: This was a double-blinded randomised control trial done in a level 3 neonatal intensive care unit. Term neonates on mechanical ventilation with an Oxygenation Index (OI) > 15, and echocardiography suggesting PPHN were included in the study. The drug group received intravenous Sildenafil and the placebo group normal saline. The difference in the mortality rate between the two groups was analysed. Results: Eleven babies were randomised to the drug group and 12 to the placebo group. Both the groups matched in terms of their baseline characteristics. The difference in the drop of OI and right ventricular systolic pressure (RVSP) between the drug and placebo groups was not statistically significant. The relative risk of mortality was 0.436 in the intervention group (95% CI 0.105 to 1.80). The difference in the mortality rate was not statistically significant with P- value of 0.252. The rate of complications such as necrotising enterocolitis, sepsis, and pneumothorax was not different between the two groups. Conclusions: Intravenous sildenafil does not have any significant benefit over placebo in reducing all-cause mortality, oxygenation index, RVSP or complications when compared to placebo.
Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review

J.N. Travadi,S.K. Patole

DOI: https://doi.org/10.1002/ppul.10389

IF: 4.0899

2003-11-10

Pediatric Pulmonology

Abstract:Persistent pulmonary hypertension of the newborn (PPHN) is a complex syndrome with multiple causes, with an incidence of 0.43-6.8/1,000 live births and a mortality of 10-20%. Survivors have high morbidity in the forms of neurodevelopmental and audiological impairment, cognitive delays, hearing loss, and a high rate of rehospitalization. The optimal approach to the management of PPHN remains controversial. Inhaled nitric oxide (iNO) is currently regarded as the gold standard therapy, but with as many as 30% of cases failing to respond, has not proven to be the single magic bullet. Given the complex pathophysiology of the disease, any such magic bullet is unlikely. A number of recent studies have suggested a role for specific phosphodiesterase (PDE) inhibitors in the management of PPHN. Sildenafil, a specific PDE5 inhibitor, appears the most promising of such agents. We aim to review the current status and limitations of iNO and the potential of PDE inhibitors in the management of PPHN. The reasons why caution is warranted before specific PDE5 inhibitors like sildenafil are labelled as potential magic bullets for PPHN will be discussed. The need for randomized-controlled trials to determine the safety, efficacy, and long-term outcome following treatment with sildenafil in PPHN is emphasized.

pediatrics,respiratory system
Cost-Utility of Sildenafil for Persistent Pulmonary Hypertension of the Newborn

Patrick D Evers,Paul J Critser,Michelle Cash,Melissa Magness,Susan Hoelle,Russel Hirsch

DOI: https://doi.org/10.1055/s-0040-1713819

Abstract:Objective: While advanced therapies for severe persistent pulmonary hypertension of the newborn (PPHN) such as inhaled nitric oxide (iNO) and extracorporeal membrane oxygenation (ECMO) are standard treatments in high-income countries, these therapies are often unavailable in resource-limited settings such as middle-income countries. However, there are small clinical trials illustrating the efficacy of sildenafil at reducing mortality in PPHN. This analysis sought to determine the cost-utility of enteral sildenafil for the treatment of severe PPHN. Study design: A Markov-state transition model was constructed for the two clinical approaches to compare costs, clinical outcomes, and quality of life: (1) "conventional," (2) "sildenafil." The impact of sildenafil was modeled as a relative risk modifier of the conventional strategy's mortality risk. Transitional probabilities, costs, and utility metrics were extracted from the literature. Sensitivity analyses for each model input as well as 100-patient Monte Carlo simulations were used to test the durability of the model conclusion. Results: The sildenafil strategy was cost-effective for upper but not lower middle-income countries with an incremental cost-effectiveness ratio of $2,339 per quality-adjusted life year. This conclusion was durable across a wide-range of model assumptions; the sildenafil strategy only failed to meet criteria for cost-effectiveness when sildenafil therapy had a mortality relative risk efficacy of >0.89, if life expectancy in that country is <40 years, or if the lifetime forecasted costs of a survivor's life was quite high. Conclusion: Enteral sildenafil is a cost-effective intervention for severe PPHN for upper middle-income countries where ECMO and iNO are not available. Key points: · PPHN is a common life-threatening condition in newborns.. · Sildenafil improves survival of PPHN.. · Sildenafil is cost-effective for upper-middle income countries..
Comparison of Efficacy between Sildenafil Alone and Sildenafil with Milrinone for Treatment of Persistent Pulmonary Hypertension of the Newborn

Maksudur Rahman,Nondini Rahman Nupur,Mohammad Abdulla Al Mamun,Md. Monir Hossain

DOI: https://doi.org/10.36347/sjams.2021.v09i10.008

2021-10-11

Scholars Journal of Applied Medical Sciences

Abstract:Introduction: In persistent pulmonary hypertension of the newborn (PPHN), some neonates do not response to single pulmonary vasodilator drug, so recently combination therapy is being tried to decrease pulmonary artery systolic pressure (PASP). The aim of the study was to compare the efficacy of oral sildenafil alone with combination of oral sildenafil and milrinone in neonates suffering from PPHN. Methods: This RCT study was conducted in Dhaka Shishu (Children) Hospital, from July 2018 to June 2020. Sixty eight (68) term and near term neonates aged <10 days (34 cases in each group) with moderate to severe PPHN were taken. Monotherapy with oral sildenafil was given in group-A and combined therapy with oral sildenafil and i/v milrinone in Group-B. Serial echocardiography was done at before starting the therapy, at 3 days and at 5 days of treatment. Data regarding baseline characteristics, clinical features, PASP, PO2, Spo2, hospital stay, mortality and others investigations were recorded and analyzed with SPSS version-26. Results: Post treatment PASP was significantly reduced in group A (sildenafil) and group-B (sildenafil plus milrinone) (p<0.05). But in combination group PASP was more reduced than monotherapy group (p<0.05). Within the group, the oxygen saturation and PO2 significantly improved in both groups (p 0.05). Adrenaline infusion, hypotension and less hospital stay were significantly seen (P<0.05) in combination group. Conclusion: Combined therapy with oral sildenafil and milrinone are more effective than monotherapy with oral sildenafil in reduction of PASP. Both therapies are effective in improvement of oxygenation.
Organizational learning model for adaptive collective behaviors in multiple robots

K. Takadama,K. Hajiri,T. Nomura,K. Shimohara,S. Nakasuka

DOI: https://doi.org/10.1163/156855398X00172

Abstract:This paper proposes a novel organizational learning model in which multiple robots acquire their own functions for adaptive collective behaviors through local interactions among their neighbors and form an organizational structure to complete given tasks without global explicit control mechanisms or communication methods. In this paper, we focus on emergent processes in which robots dynamically form an organizational structure by acquiring their own appropriate functions to complete given tasks effectively and also focus on how organizational knowledge supports robots to reform their organizational structure. Through intensive simulations of truss construction by multiple robots, the following experimental results have suggested: (1) robots in our model acquire their own appropriate functions without global explicit control mechanisms or communication methods and form an organizational structure which completes given tasks in less steps than those with a centralized control system, and (2) organizational ...
The carbohydrate CT 1 is expressed in topographically fixed glomeruli in the mouse olfactory bulb

K. Lineburg,D. Amaya,J. Ekberg,Fatemeh Chehrehasa,Alan,Mackay-Sim,Paul T. Martin,B. Key,J. A. John

Abstract:
Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial

Aditya Kallimath,Sujata Deshpande,Pari Singh,Reema Garegrat,Satyan Lakshminrusimha,Rajesh Maheshwari,Pradeep Suryawanshi

DOI: https://doi.org/10.1186/s12887-024-05107-0

2024-11-03

BMC Pediatrics

Abstract:Access to inhaled nitric oxide (iNO) is limited in low resource settings due to non-availability and high cost. There is a need for research on low-cost alternative therapies for management of persistent pulmonary hypertension of the newborn (PPHN). We aimed to compare oral sildenafil and bosentan as monotherapy in the treatment of neonates with PPHN.

pediatrics
Use of sildenafil for the treatment of neonatal persistent pulmonary hypertension

José de Ribamar Barroso Jucá Neto,Ângela Rocha Mapurunga,Angelica Gomes Belchior,Felipe Rabelo Costa,Vitor Teixeira Boscov

DOI: https://doi.org/10.33448/rsd-v13i1.44910

2024-01-31

Abstract:Introduction: Persistent pulmonary hypertension of the newborn is a neonatal respiratory and vascular pathology with a high mortality rate. Furthermore, its prevalence is 1 to 2 per 1000 live births, accounting for 8%-10% of neonatal deaths. The therapeutic approach involves supporting pulmonary recruitment and pharmacological vasodilation, most notably sildenafil. Methodology: The study is a narrative review of the literature that was carried out from the PUBMED database using the keywords “Persistent Pulmonary Hypertension of the Newborn” and “Sildenafil”, with the time filter in the last 30 years (1994- 2023). Discussion: Physiologically, during fetal life, the lungs remain filled with fluids, but immediately after birth, pulmonary vascular resistance decreases drastically, allowing alveolar oxygen tension and ventilation to be possible. However, in the pathogenesis of neonatal persistent pulmonary hypertension, there is an increase in pulmonary vascular resistance and remodeling of the vascular structure after birth, which potentiate this exaggerated vasoconstriction. Therefore, the standard exam for investigating the pathology is echocardiography. Sildenafil is a drug used to treat neonatal persistent pulmonary hypertension, as it enhances better blood flow and better delivery of oxygen to tissues, through its physiopharmacology aimed at vasodilation secondary to inhibition of phosphodiesterase-5. Conclusion: Neonatal persistent pulmonary hypertension is still one of the main neonatal pathologies with high morbidity and mortality in the neonatal population, due to the complexity of presentations and the variation in therapeutic responses to pharmacotherapy.
Oral drugs used to treat persistent pulmonary hypertension of the newborn

Wei Zhang,Yue-E Wu,Xiao-Yan Yang,Jing Shi,John van den Anker,Lin-Lin Song,Wei Zhao

DOI: https://doi.org/10.1080/17512433.2020.1850257

Abstract:Introduction:Persistent Pulmonary Hypertension of the Newborn (PPHN) is a life-threatening neonatal condition, mostly treated with inhaled nitric oxide (iNO), intravenous prostaglandins, oral bosentan, sildenafil and tadalafil. However, the utility of non-oral agents is limited in PPHN for their side effects and inconvenient deliveries. Therefore, oral agents such as bosentan, sildenafil and tadalafil are becoming appealing for their satisfactory efficacy, easy mode of administration and acceptable side effects. Areas covered: We conducted a comprehensive search on Pubmed, Scopus, Web of Sciences concerning the use of bosentan, sildenafil and tadalafil to treat PPHN and summarized their efficacy, safety and pharmacokinetics. Expert opinion: Current randomized controlled trials (RCTs) have demonstrated the favorable responses and tolerable side effects of bosentan and sildenafil. Nevertheless, those RCTs are small and only one study has described the pharmacokinetics of sildenafil in neonates. Accordingly, bosentan, sildenafil and tadalafil remain off-label in clinical use. More well-designed RCTs with large samples and long-term follow-up and pharmacometrics studies are needed to demonstrate the efficacy, safety and pharmacokinetics of bosentan, sildenafil and tadalafil in PPHN.
Comparison of treprostinil and oral sildenafil for the treatment of persistent pulmonary hypertension of the newborn: a retrospective cohort study

Enhuan Wei,Xiu-hua Chen,Si-Jia Zhou

DOI: https://doi.org/10.3389/fped.2023.1270712

IF: 3.569

2023-11-04

Frontiers in Pediatrics

Abstract:Background: This study aims to evaluate the effectiveness of treprostinil and oral sildenafil in managing persistent pulmonary hypertension of newborns (PPHN). Methods: We conducted a retrospective cohort study of 42 neonates with PPHN treated with continuous intravenous treprostinil or oral sildenafil from January 2020 to October 2022 in China. Outcomes assessed included echocardiographic pulmonary artery systolic pressure (PASP), shunt direction, and arterial blood gas measures. Results: Treprostinil lowered PASP and improved oxygenation significantly better than sildenafil on days 1, 2, and 3 of treatment ( P < 0.05). Treprostinil also corrected shunt direction faster than sildenafil ( P < 0.05). The duration of mechanical ventilation, length of NICU stay, and overall hospital stay did not significantly differ between the two groups ( P > 0.05). Conclusions: Treprostinil effectively lowers pulmonary artery pressure and improves oxygenation in neonates with PPHN, without being associated with severe complications. It may serve as a beneficial adjunct therapy for neonates with PPHN.

pediatrics
Sildenafil as Bridge Therapy for Inhaled Nitric Oxide in Preterm Neonates

Harris Khawaja,Timothy A Sanders,Michael Schreiber,Deborah Bondi,Pooja Shah,Gillian Brennan

DOI: https://doi.org/10.5863/1551-6776-29.5.525

Abstract:Objective: Inhaled nitric oxide (iNO) is a mainstay of treatment for infants with persistent pulmonary -hypertension. However, abrupt discontinuation of inhaled nitric oxide can result in rebound pulmonary -hypertension. The objective of this analysis is to describe the use of sildenafil to facilitate the weaning from iNO in preterm neonates. Methods: This retrospective chart review identified all infants who were receiving iNO and subsequently received sildenafil between 2017 and 2021. Neonates were included if they met the following criteria: gestational age at birth less than 34 weeks, receiving iNO, and started on sildenafil with the indication to facilitate weaning or discontinuation of iNO. Patients were excluded if they had major congenital anomalies, including congenital heart disease or congenital diaphragmatic hernia. Results: We identified 7 neonates with a gestational age range of 22 5/7 weeks to 31 0/7 weeks and birth weight range of 545 to 910 g with previously failed attempts at iNO weaning. The most common starting dose for sildenafil was 0.125 mg/kg intravenously every 8 hours or 0.25 mg/kg enterally every 8 hours. Four infants were able to discontinue iNO within 48 hours of sildenafil initiation, 1 patient discontinued iNO within 5 days, and 1 patient within 10 days of sildenafil initiation. One patient experienced weaning failure from iNO despite initiation of sildenafil. No adverse events, such as hypotension or deaths, were reported in any of the 7 infants. Conclusions: Sildenafil facilitated weaning off iNO in most preterm neonates evaluated without adverse side effects.
Persistent Pulmonary Hypertension of the Newborn: The Efficacy Comparison of Vasodilators Sildenafil Plus Bosentan Versus Sildenafil Plus Beraprost at a Tertiary Childcare Health Facility

Mudasser Adnan,Muhammad Sohail Arshad,Hafiz Muhammad Anwar-ul-Haq,Munir Ahmad,Hira Afsheen,Hashim Raza

DOI: https://doi.org/10.7759/cureus.20020

2021-11-29

Cureus

Abstract:Background Persistent pulmonary hypertension of the newborn (PPHN) has been known for more than three decades, and lots of advancements have been made regarding its diagnosis and management. However, the exact causes of PPHN and the best treatment strategies remain debatable. This study aimed to compare the effectiveness of sildenafil and bosentan versus sildenafil and beraprost in the management of persistent pulmonary hypertension of the newborn (PPHN). Methodology This open-label, non-randomized, quasi-experimental study was conducted at the Department of Pediatric Cardiology and Neonatology, The Children's Hospital & The Institute of Child Health, Multan, Pakistan, from January 2021 to June 2021. We enrolled a total of 50 newborns (25 in each group) aged <10 days, gestational age above 34 weeks, who presented with respiratory distress and marked hypoxemia (PaO2 < 50 mmHg) as per arterial blood gas (ABG) analysis and confirmed echocardiographic diagnosis of PPHN within 24 hours of admission. A total of 25 cases were given sildenafil and bosentan, while the other 25 cases were given sildenafil and beraprost. Echocardiographic examination was done again after 72 and 120 hours, and the findings were noted. Outcomes were measured in terms of the reduction in tricuspid regurgitation (TR), mortality, and duration of hospital stay. Results Of the 50 neonates, 27 (54.0%) were male. Overall, the mean age was calculated to be 3.54 ± 0.7 days. The mean gestational age was 35.0 ± 0.7 weeks. The mode of delivery was cesarean section among 35 (70.0%) neonates. A significantly higher reduction in tricuspid regurgitation after 72 and 120 hours following the initiation of the treatment was observed in the sildenafil plus bosentan group in comparison with the sildenafil plus beraprost group (p < 0.05). No statistically significant difference was observed in terms of the duration of hospitalization between both study groups (p = 0.1776). Conclusion The combination of sildenafil and bosentan was found to be more effective than sildenafil and beraprost in reducing tricuspid regurgitation after 72 hours, while they have comparable efficacy at 120 hours of treatment in the management of persistent pulmonary hypertension of the newborn.
Comparison of Different Treatments of Persistent Pulmonary Hypertension of the Newborn: A Systematic Review and Network Meta-Analysis

Qiang Fei,Jiarong Pan,Feizhou Zhang,Yu Lin,Tianming Yuan

DOI: https://doi.org/10.1097/ccm.0000000000006227

IF: 8.8

2024-02-16

Critical Care Medicine

Abstract:Objectives: Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening disease. Despite being considered the gold standard treatment scheme, inhaled nitric oxide (iNO) is not readily available in settings with limited resources. Therefore, in recent years, research on related drugs is being actively pursued. Herein, we aimed to use random-effects network meta-analysis to evaluate the efficacy and associated mortality of different PPHN therapies. Data Sources: We electronically searched the PubMed, Embase, and Cochrane Library for data up to January 27, 2023. Study Selection: Randomized controlled trials involving neonates with PPHN assessing efficacy and mortality of various treatments. Data Extraction: Details of study population, treatments, and outcomes were extracted. Data Synthesis: Direct pairwise comparisons and a network meta-analysis was performed under random effects. The ranking probability was further assessed based on the surface under the cumulative ranking curve (SUCRA). We analyzed 23 randomized clinical trials involving 902 newborns with PPHN. Sixteen different treatment strategies were compared with each other and conventional therapy (CON). A median concentration of 10–20 parts per million (ppm) iNO (MNO) coupled with sildenafil orally administered at a dose of 1–3 mg/kg/dose every 6–8 hours (OSID) demonstrated the best efficacy (MNO + OSID vs. CON: odds ratio [OR] = 27.53, 95% CI, 2.36–321.75; SUCRA = 0.818, ranking first; moderate quality). OSID combined with milrinone administered IV also performed well in terms of efficacy (OSID + milrinone vs. CON: OR = 25.13, 95% CI = 1.67–377.78; SUCRA = 0.811, ranking second; low quality) and mortality reduction (CON vs. OSID + milrinone: OR = 25.13, 95% CI = 1.67–377.78; SUCRA = 0.786, ranking last; low quality). Conclusions: MNO + OSID is the most effective PPHN treatment. If iNO is not available, OSID + milrinone is preferred.

critical care medicine

Perforation of the right ventricular free wall by an ICD lead in a patient with isolated noncompaction of the ventricular myocardium.

Effect of Sildenafil in Neonates with Persistent Pulmonary Hypertension: An Interventional Study

Efficacy of sildenafil in persistent pulmonary hypertension of the newborn.

Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital

Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study

The outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn with respiratory distress

The use of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Review of the Literature

Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial

Effect of Sildenafil on Mortality in Term Neonates with Hypoxemic Respiratory Failure due to Persistent Pulmonary Hypertension (SIPHON) - A Randomised Control Trial

Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review

Cost-Utility of Sildenafil for Persistent Pulmonary Hypertension of the Newborn

Comparison of Efficacy between Sildenafil Alone and Sildenafil with Milrinone for Treatment of Persistent Pulmonary Hypertension of the Newborn

Organizational learning model for adaptive collective behaviors in multiple robots

The carbohydrate CT 1 is expressed in topographically fixed glomeruli in the mouse olfactory bulb

Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial

Use of sildenafil for the treatment of neonatal persistent pulmonary hypertension

Oral drugs used to treat persistent pulmonary hypertension of the newborn

Comparison of treprostinil and oral sildenafil for the treatment of persistent pulmonary hypertension of the newborn: a retrospective cohort study

Sildenafil as Bridge Therapy for Inhaled Nitric Oxide in Preterm Neonates

Persistent Pulmonary Hypertension of the Newborn: The Efficacy Comparison of Vasodilators Sildenafil Plus Bosentan Versus Sildenafil Plus Beraprost at a Tertiary Childcare Health Facility

Comparison of Different Treatments of Persistent Pulmonary Hypertension of the Newborn: A Systematic Review and Network Meta-Analysis